Discovery principles

Aeviant uses explicit scientific rules to keep therapeutic design connected to the disease question and the evidence.

State a falsifiable physiological question

Every program defines the dysregulated state, the useful function to preserve and the therapeutic response being investigated. The hypothesis must identify an observation that would challenge it.

Design from the required behaviour

Target, modality and molecular design are chosen in relation to the required pharmacology. State, timing, signalling, endogenous demand and functional consequence are treated as explicit design variables when the biology makes them relevant.

Challenge models before advancing them

Literature claims are checked against their sources. Computational methods are tested against appropriate controls, alternative explanations and predefined failure criteria. Reproducibility and method fitness are assessed before an output informs a program decision.

Translate predictions into experiments

Computational work characterizes targets, generates molecular hypotheses and prioritizes direct tests. Synthesis and experimental pharmacology provide the next evidence for molecular and functional claims.

Follow the result

Results can support the current design, expose a different pharmacological direction or end the line of work. Aeviant records those decisions and updates the program when the evidence changes.